Alicia GalarValerio Minero, MaricelaMuñoz García, Patricia CarmenAlcalá, LuisGarcía-González, XandraBurillo Albizua, AlmudenaSanjurjo, MaríaGrau, SantiagoBouza Santiago, Emilio2025-01-292025-01-292017Galar A, Valerio M, Muñoz P, Alcalá L, García-González X, Burillo A, Sanjurjo M, Grau S, Bouza E. Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00687-17. doi: 10.1128/AAC.00687-17. PMID: 28739788; PMCID: PMC5610525.0066-48041098-659610.1128/aac.00687-17https://hdl.handle.net/20.500.14352/116861Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.engjournal articlehttps://doi.org/10.1128/AAC.00687-17restricted access613.83Linezolidtherapeutic drug monitoringdrugs for Gram-positive bacteriaCiencias Biomédicas32 Ciencias Médicas